79 related articles for article (PubMed ID: 8032067)
1. Effects of ilexonin A on cAMP metabolism in platelets.
Wang Z; Li F
Chin Med Sci J; 1993 Dec; 8(4):215-7. PubMed ID: 8032067
[TBL] [Abstract][Full Text] [Related]
2. [Ilexonin A may be a slow calcium channel blocker].
Wang L; Wang Z
Zhong Xi Yi Jie He Za Zhi; 1989 Nov; 9(11):668-71, 645. PubMed ID: 2611956
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of human platelet adenylate cyclase by prostaglandin D2.
Mills DC; Macfarlane DE
Thromb Res; 1974 Sep; 5(3):401-12. PubMed ID: 4373870
[No Abstract] [Full Text] [Related]
4. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets.
Nogimori K; Kajikawa N; Nishio S; Yajima M
Prostaglandins; 1989 Feb; 37(2):205-12. PubMed ID: 2543034
[TBL] [Abstract][Full Text] [Related]
5. Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes.
Seiler S; Arnold AJ; Grove RI; Fifer CA; Keely SL; Stanton HC
J Pharmacol Exp Ther; 1987 Nov; 243(2):767-74. PubMed ID: 2824759
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human platelet aggregation by parathyroid hormone. Is cyclic AMP implicated?
Benigni A; Livio M; Dodesini P; Schieppati A; Panigada M; Mecca G; de Gaetano G; Remuzzi G
Am J Nephrol; 1985; 5(4):243-7. PubMed ID: 2996352
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers.
Gasser JA; Betterridge DJ
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S29-34. PubMed ID: 1721976
[TBL] [Abstract][Full Text] [Related]
8. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
[TBL] [Abstract][Full Text] [Related]
9. Effect of chilling on platelet cyclic adenosine 3:5-monophosphate and adenylate cyclase activity.
Zappia GC; Steiner M; Ando Y; Baldini M
Transfusion; 1976; 16(2):122-9. PubMed ID: 176753
[TBL] [Abstract][Full Text] [Related]
10. DL-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and phosphodiesterase.
Ye J; Zhai L; Zhang S; Zhang Y; Chen L; Hu L; Zhang S; Ding Z
Platelets; 2015; 26(8):736-44. PubMed ID: 25734213
[TBL] [Abstract][Full Text] [Related]
11. In vitro effects of ethanol on rabbit platelet aggregation, secretion of granule contents, and cyclic AMP levels in the presence of prostacyclin.
Rand ML; Gross PL; Jakowec DM; Packham MA; Mustard JF
Thromb Haemost; 1989 Apr; 61(2):254-8. PubMed ID: 2546284
[TBL] [Abstract][Full Text] [Related]
12. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
Benjamin CW; Lin AH; Morris J; Wishka DG; Gorman RR
J Pharmacol Exp Ther; 1993 Apr; 265(1):457-62. PubMed ID: 7682615
[TBL] [Abstract][Full Text] [Related]
13. 18O labeling of adenine nucleotide alpha-phosphoryls in platelets. Contribution by phosphodiesterase-catalyzed hydrolysis of cAMP.
Walseth TF; Gander JE; Eide SJ; Krick TP; Goldberg ND
J Biol Chem; 1983 Feb; 258(3):1544-58. PubMed ID: 6296104
[No Abstract] [Full Text] [Related]
14. Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry.
Kageyama K; Mizobe T; Nozuchi S; Hiramatsu N; Nakajima Y; Aoki H
J Anesth; 2004; 18(2):107-12. PubMed ID: 15127258
[TBL] [Abstract][Full Text] [Related]
15. [Cyclic nucleotides and blood platelet functions].
Kuramoto A
Nihon Rinsho; 1978 Dec; 36(12):3813-8. PubMed ID: 34743
[No Abstract] [Full Text] [Related]
16. [Effect of ilexonin A on platelet function and ultrastructure].
Wang Z; Du JX
Zhong Xi Yi Jie He Za Zhi; 1985 Apr; 5(4):232-4, 197. PubMed ID: 3158445
[No Abstract] [Full Text] [Related]
17. Platelet cyclic AMP in essential hypertension.
Mazeaud MM; Le Quan Sang KH; Devynck MA
J Hypertens; 1989 Jun; 7(6):501-6. PubMed ID: 2550542
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
19. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
20. Mechanism involved in the antiplatelet activity of naloxone in human platelets.
Sheu JR; Hung WC; Lee LW; Chang PT; Kan YC; Yen MH
Biochem Biophys Res Commun; 1997 Feb; 231(1):12-6. PubMed ID: 9070210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
